By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Fortress Biotech (Formerly Known As Coronado Biosciences) 

2 Gansevoort Street
9th Floor
New York  New York  10014  U.S.A.
Phone: 781-652-4500 Fax: n/a


SEARCH JOBS

Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. Additionally, Fortress recently acquired a controlling interest in National Holdings Corporation (NASDAQ: NHLD), a diversified independent brokerage company (together with its subsidiaries, “NHLD”). In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs.

YEAR FOUNDED:

2006

LEADERSHIP:

CEO: Lindsay A. Rosenwald

CFO: Lucy Lu

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products

FOLLOW FORTRESS BIOTECH:




Key Statistics


Email: info@fortressbiotech.com
Ownership: Public

Web Site: Fortress Biotech
Employees:
Symbol: FBIO
 




Segment
Start Up





Company News
Fortress Biotech (FBIO) Surged After Reporting Big Success With CAR-T Cancer Approach 12/29/2016 7:05:21 AM
Fortress Biotech (CNDO) Forms Cellvation, Taps Forest (FRX), Life Technologies (LIFE) Alum as Interim CEO 11/7/2016 6:51:27 AM
Fortress Biotech (CNDO)'s Avenue Therapeutics Files Form 10 to Go Public 12/30/2015 6:44:18 AM
Fortress Biotech (CNDO) Reports Financial Results For The Third Quarter 2015 Ended September 30, 2015 11/9/2015 8:46:17 AM
Fortress Biotech (CNDO) Reports Financial Results For The Second Quarter 2015 Ended June 30, 201 8/10/2015 10:22:53 AM
Fortress Biotech (CNDO) Subsidiary, Altamira Bio, Acquires NIH License And Cradas Relating To The Development Of N-Acetyl-D-Mannosamine (Mannac) For Rare Genetic Disorders 7/17/2015 7:20:55 AM
Fortress Biotech (CNDO) Reports Financial Results For The First Quarter 2015 Ended March 31, 2015 5/11/2015 8:37:25 AM
Coronado Biosciences (CNDO) Changes Its Name To Fortress Biotech 4/27/2015 7:57:51 AM
Coronado Biosciences (CNDO) Forms New Subsidiary, Diavax Biosciences, To Develop Novel Immunotherapies For Cytomegalovirus 4/2/2015 7:14:26 AM
Coronado Biosciences (CNDO) Announces Exclusive Licensing Agreement With Neupharma To Develop And Commercialize Novel Covalent 3rd Generation EGFR Inhibitors 3/19/2015 7:38:45 AM
12345678910...
//-->